Navigation Links
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Date:11/11/2013

ers us greater flexibility to accelerate these programs," concluded Mr. Milinazzo.

Operational Overview On October 29, 2013, the Company announced the 12-month follow up results from the MASTER trial for its MGuard Embolic Protection Stent (EPS).The findings showed that the novel MGuard EPS provides a significant acute advantage in reducing ST segment elevation versus traditional bare metal and drug eluting stents. As a result, MGuard may hold the potential to prolong the survival of heart attack victims, as evidenced by the 12-month data.  The 12-month follow up results are an important data point for physicians evaluating the MGuard, as the first year is an important period for evaluating a patient who has received a stent during a heart attack.  As the Company now has this data in hand, it intends to ramp commercial activity for the remainder of 2013 and 2014.

The Company continues enrollment in its MASTER II clinical trial to evaluate the safety and effectiveness of the MGuard™ Prime EPS in patients suffering from ST Elevation Myocardial Infarction (STEMI). In total, the multi-center, randomized trial is expected to include up to 70 sites in the U.S. and Europe and as many as 1,114 patients. The results are intended to support the Company's Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) to market the MGuard™ Prime MicroNet™ covered coronary stent system in the U.S.

While the MASTER II trial is fully funded, the Company took additional steps to secure strategic financing and protect shareholder value.  On October 24th, the Company announced it had secured $10 million in venture debt to support expanding its emerging clinical research and product development efforts.  The Company also put into place a one year stockholder rights plan which the Board believed was prudent in order to protect shareholders' interests. 

Quarter Ended S
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... -- AbbVie (NYSE: ABBV ) will participate in the ... on Thursday, Nov. 20, 2014. Bill Chase , ... formal presentation on the company at 9:20 a.m. GMT (3:20 ... of the presentation will be accessible through AbbVie,s Investor Relations ... the session will be available later that day. ...
(Date:11/17/2014)... , Nov. 17, 2014   Wilson Therapeutics ... start of a Phase 2 clinical study to evaluate ... in Wilson Disease, a rare genetic disorder and designated ... process copper. "We are delighted to proceed ... as a next step in the development program for ...
(Date:11/16/2014)...  Hanger, Inc. (NYSE: HGR ) announced ... third quarter 2014 financial results and is cancelling its ... for the completion and review of its third quarter ... financial results and reschedule its conference call after the ... About Hanger, Inc. – Built on the ...
Breaking Medicine Technology:Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 2Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 3
... , SINGAPORE, Dec. 15 ... it has completed the previously announced acquisition of SloMedical ... ranging from tubing sets to complex devices for minimally-invasive ... set of capabilities to medical device, medical equipment, and ...
... Open enrollment is an opportune time to find the best ... 15 Through the end of the year, thousands of Nebraska ... This is when the state,s 268,000 Medicare beneficiaries get to ... in 2010. , Prescription drug coverage is a critical part ...
Cached Medicine Technology:Flextronics Completes SloMedical Acquisition 2Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans 2
(Date:11/18/2014)... Dennis Thompson HealthDay ... -- An experimental antibody drug could prove effective at ... side effects with cholesterol-lowering statin medications. That,s the ... American Heart Association annual meeting in Chicago. The ... the most widely used alternative to statins, Zetia, said ...
(Date:11/18/2014)... November 18, 2014 Financing for ... on innovative financing for international development, has announced ... Membership includes six Directors: Mr. John Skibiak of ... of the Millennium Challenge Corporation, Mr. Pape Gaye ... Impact Advisors, Mr. Aron Betru of Financing for ...
(Date:11/18/2014)... A+ Secure Packaging, a leading ... supplements and more, announced today that its LaVergne ... Practices (GMP) Registration for dietary supplements and athletic ... International verifies the A+ Secure Packaging facility meets ... of its clients by demonstrating the proper methods, ...
(Date:11/18/2014)... News) -- Hispanic women who,ve had at least five children ... heart trouble than those who,ve had fewer children or none, ... by Shivani Aggarwal of Wake Forest School of Medicine analyzed ... Miami, New York City and San Diego. About 12 percent ... A type of heart trouble called ventricular diastolic dysfunction ...
(Date:11/18/2014)... MONDAY, Nov. 17, 2014 (HealthDay News) -- Until recently, insect-transmitted ... America, but it has made its way to the United ... fatal illness is typically transmitted via the bite of the ... night. And now a new study suggests that common bedbugs ... bedbug can acquire and transmit the parasite. Our next step ...
Breaking Medicine News(10 mins):Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Financing for Development Corp. (F4D) Announces Board of Directors 2Health News:Financing for Development Corp. (F4D) Announces Board of Directors 3Health News:Financing for Development Corp. (F4D) Announces Board of Directors 4Health News:A+ Secure Packaging, LLC Earns NSF International Good Manufacturing Practices (GMP) Registration for Dietary Supplements and Certification for Sport 2Health News:Certain Heart Dysfunction More Likely in Hispanic Women With Many Kids: Study 2Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 2Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 3
... MONTREAL, Sept. 21 Presagia, provider of ... announced the release of its ADA Toolkit, which will ... FMLA (Family and Medical Leave Act) and ADA (Americans ... supplement Presagia,s Leave Management solution, which enables customers to ...
... For the past 18 months, Atlantic has been partnering ... and production of a hands-on, interactive exhibit to be installed ... create an interactive environment that would reduce the anxiety of ... James Morris, Director of Business Development. "At the onset, I ...
... , SANTA ROSA, Calif., Sept. 21 Osseon ... cement delivery needle) and Osseoflex DR (steerable and curvable bone ... for marketing and clinical use in the European Union. , ... FDA approval in the United States, and allows for the ...
... , , , ... US, Inc. ("Astellas"), in partnership with the National Science Teachers ... Chicago-area science teachers to participate in the 2009 NSTA New ... teachers to a range of tools and resources, while providing ...
... The Defense Advanced Research Projects Agency (DARPA), the research arm ... $19.5 million for an effort led by the Duke Institute ... easy-to-use diagnostic device that can reveal who is infected with ... DARPA is interested in such a device because ...
... that individuals use a variety of cues to identify their ... than their own. A new study shows that their success ... families are the same race as themselves. In ... ("Cross-cultural perceptions of facial resemblance between kin"), French and ...
Cached Medicine News:Health News:Presagia Solution Helps Employers Navigate Overlapping ADA and FMLA Regulations 2Health News:Presagia Solution Helps Employers Navigate Overlapping ADA and FMLA Regulations 3Health News:Atlantic Partners with Children's Hospital of Philadelphia to Create an Interactive & Educational Waiting Room 2Health News:Osseon Receives CE Mark 2Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 2Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 3Health News:DARPA awards Duke $19.5 million to detect viral infection before symptoms appear 2Health News:Race has little effect on people's ability to spot family resemblances 2
Shandon Plastic Slide Boxes...
Shandon Cardboard Slide Folders...
... The new Propaq LT is the ... environment--combining the basic parameters of continuous vital ... new design, making it perfect for just ... place. , Light enough to clip on ...
Exxcel Soft ePTFE vascular graft, designed for exceptional kink resistance and crush resistance, maintains a Soft touch for easier handling during peripheral vascular bypass procedures and vascular a...
Medicine Products: